The Clinical Relevance of Immune Cells and CTC in HNSCC Patients

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

300 participants

Study Classification

OBSERVATIONAL

Study Start Date

2015-01-31

Study Completion Date

2018-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Head and neck squamous cell carcinomas (HNSCCs) are mainly caused by tobacco, alcohol consumption and betel nut chewing and the sixth most common cancer in the world. Despite significant advances in the treatment modalities involving surgery, radiotherapy, and concomitant chemoradiotherapy, the 5-year survival rate remained below 50% for the past 30 years.

The worse prognosis of these cancers must certainly be linked to the fact that HNSCCs strongly influence the host immune system. During this process, mesenchymal tumor-like cells are highly mobile and enter quickly adjacent structure (intravasation), from where they travel through lymphatic and blood vessels as circulating tumor cells (CTC), which are single cells with malignant potential detected in the peripheral bloodstream and essential for establishing metastasis.

Programmed death 1 (PD-1) and its ligand (PD-L1) play pivotal roles in regulating host immune responses. Substantial evidence has demonstrated that PD-L1 can deliver an inhibitory signal to PD-1 expressing T cells, leading to suppression of the immune response by inducing apoptosis, energy, unresponsiveness and functional exhaustion of T cells. However, the inhibitory effects of this pathway on the function of cytotoxic T lymphocytes, the main effector cells in HNSCC patients, are not well defined.

In this study aims to solve two main problems: one is to improve and try to optimize current protocols of CTC isolations based on the investigator previous work, which is one of most challenging problems in CTC field to date; the other is to understand the status of immune system in HNSCC patients, especially focusing on PD-1-PD-L1 pathway and its expressions. After series basic experiments of immune cell analysis and conditional adjustment of CTC isolation protocols, the investigator are willing to isolate CTCs and immune cells at a single blood drawing at the same time. A prospective trial will be conducted to elucidate the roles of PD-1 expression lymphocytes and CTC numbers on the clinical outcomes of HNSCC patients.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Prognostic Value of CTC in HNSCC Patients

NCT01884129

Recurrence Metastasis Death

TERMINATED

The Clinical Study of the Poorly Differentiated Head and Neck Squamous Cell Carcinoma

NCT02916368

Carcinoma, Squamous Cell

UNKNOWN

Effectiveness and Safety of Nivolumab in Participants That Have Head and Neck Cancer That Has Come Back or Has Spread

NCT03569436

Cancer of Head and Neck Cancer of the Head Cancer of the Neck

COMPLETED

A Study for Identification of Immune Determinants for Response to Nivolumab in Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma

NCT04603248

Head and Neck Squamous Cell Carcinoma (HNSCC)

UNKNOWN NA

Rituximab Plus Chemotherapy in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma

NCT04361409

Head and Neck Squamous Carcinoma

COMPLETED PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

1. To establish a platform to increase the efficiency and purity for isolation and enumeration of circulating tumor cells from patients with head and neck cancer.
2. Compare the differences and determine the most efficient method or combination of negative, positive selection, optoelectronic dielectrophoresis (ODEP) and flow cytometry sorting technology.

1. Negative Selection
2. Positive Selection
3. ODEP devices
4. Flow Cytometry and Sorting System
3. Use the upgraded platform and test among different groups for efficiency test. (Planned subjects: healthy donor: n=30; early-stage (stage I=II) patients=9; locally-advanced=9 and metastatic, n=9; total n=60)

\- Clinical Enrollment for Device/Method Validation
4. To confirm programmed death-1(PD-1) expression could be successfully detected and up-regulated on cytotoxic T cells using cell lines natural killer cell (NK-92).

1. Cell Culture of NK-92, OECM-1, SCC-4 and K562
2. Immunostaining methods for PD-1 expression
3. Flow cytometry for ratio of PD-1 expression
5. To observe the functional changes of the cytotoxic T cells with PD-1 expression using cell lines and immunomagnetic bead-based isolation method.

1. Positive Isolation for PD-1 Expressing Cells
2. CD107a cytotoxicity assay
3. Cell-mediated cytotoxicity assays
6. Confirm these findings in whole blood sample from healthy donors (n=15) and HNSCC patients (n=15).

\- Clinical Enrollment Patients for PD-1 expression in PBMCs, a stage of validation previous findings
7. Using the platform established on first-year project, to isolate and check the CTC number from locally advanced or metastatic HNSCC patients for validation.
8. To check the ratio of circulating CD56+ cells with PD-1 expression from locally advanced or metastatic HNSCC patients for validation.
9. To correlate the clinical relevance of circulating PD-1+CD56 cells and CTCs in locally advanced or metastatic HNSCC patients (N=60 in this year). Another Healthy donors (n=15) will be needed for reference.

1. CTC enumeration and sorting technique-Negative Selection Strategy
2. Positive Selection
3. ODEP devices
4. Flow Cytometry and Sorting System
5. Clinical Enrollment HNSCC Patients for CTCs and PD-1 ratio

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Recurrence Metastasis Death

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Established head and neck squamous cell carcinoma.
2. Age \>=20 years old with clear consciousness, decided by free wills.

Ability to sign informed consent

Exclusion Criteria

1. Patient's refusal
2. Poor compliance, cannot draw blood for CTCs isolation as time schedule or clinical treatment or follow-up
3. Difficult blood sampling
4. No more needs for CTCs evaluation, decided by clinicians.

Inability to comply with study and/or follow-up procedures.

Minimum Eligible Age

20 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes